Parabilis Medicines CMO Fawzi Benzaghou to depart effective Sept 30, 2026

Parabilis Medicines, Inc.

Chief Medical Officer Fawzi Benzaghou, M.D. and company mutually agreed to his transition, effective September 30, 2026.
Dr. Benzaghou will receive severance benefits pursuant to his employment agreement.
No replacement CMO has been named in the filing.

item 5.02

Parabilis Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-380171

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.